Technology

A CRISPR/AI driven foundry for precision immune cell engineering

To accelerate the path to the clinic, Artisan’s revolutionary cell foundry creates custom-engineered cells for therapeutic applications. The foundry utilizes Artisan’s STAR platform, which builds upon our deep expertise in CRISPR-enabled multiplex cell engineering by combining a proprietary family of novel endonuclease editing systems with high-throughput workflows and data analysis. 

This platform has been proven out across many relevant cell types including T cells, iPSC, primary cells, cancer cells, as well as with industrial cell lines like CHO or HEK293. Moreover, our platform reproducibly deliveries superior editing efficiencies (>90%) that enable entirely new cell therapy strategies for increasing efficacy and/or safety.

See the Difference

Current viral-based cell therapy platforms cannot capture the same amount of value because of their inability to identify and optimize high-value candidate cell therapy designs.

Artisan’s approach is either fully non-viral or can be combined with viral payload (CAR) delivery, providing solutions based on a more comprehensive understanding of how different cell therapy design strategies affect indicators of clinical performance in shortened timelines.

Candidate Development

VS
Faster Process

Artisan Cell Therapeutics

Hit Generation

Lead Selection

Lead Optimization

Lead Characterization

High Value
Candidate
Selection

Slower Process

Viral Cell Therapeutics

unable
to
perform

Lead Selection

unable
to
perform

Lead Characterization

Candidate
Selection

How it Works

The foundry builds designer cells using a comprehensive and proprietary high-throughput screening workflow that scales from 1-10,000’s of edits, then tests lead candidates across a panel of genotypic and phenotypic assays, resulting in the identification and selection of the best cell therapy candidates for clinical development.

Our differentiation lies in our vision and approach to cell engineering, which is based on decades of solving complex cell engineering challenges through the generation of innovative technology platforms.

Broadly Proving our Platform

High Value Cells

Our ability to successfully edit IPSCs, T-cells, and other relevant cell types gives us a significant lead in quickly creating highly active cell therapy candidates.

Novel Engineered Crispr systems

Artisan’s proprietary STAR endonuclease editing systems and platform for discovery and optimization provide for a clear path to market for CRISPR engineered cell therapies without any FTO barriers.

AI Learning Platform

Our design algorithms utilize machine learning to increase on-target editing activity while minimizing off-targets; continuous data feedback constantly increases the accuracy of our predictive models.

High-Throughput Cell Characterization

Our high-throughput testing and analysis of genomic, proteomic, and phenotypic characteristics to ensure that we have the data you need to move your therapeutic candidate into clinical studies.